Literature DB >> 25540272

Tuberculosis vaccine types and timings.

Ian M Orme1.   

Abstract

Traditionally, the design of new vaccines directed against Mycobacterium tuberculosis, the most successful bacterial pathogen on the planet, has focused on prophylactic candidates that would be given to individuals while they are still young. It is becoming more apparent, however, that there are several types of vaccine candidates now under development that could be used under various conditions. Thus, in addition to prophylactic vaccines, such as recombinant Mycobacterium bovis BCG or BCG-boosting vaccines, other applications include vaccines that could prevent infection, vaccines that could be given in emergency situations as postexposure vaccines, vaccines that could be used to facilitate chemotherapy, and vaccines that could be used to reduce or prevent relapse and reactivation disease. These approaches are discussed here, including the type of immunity we are trying to specifically target, as well as the limitations of these approaches.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25540272      PMCID: PMC4340897          DOI: 10.1128/CVI.00718-14

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  87 in total

1.  Boosting vaccine for tuberculosis.

Authors:  J V Brooks; A A Frank; M A Keen; J T Bellisle; I M Orme
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

2.  The Achilles heel of BCG.

Authors:  Ian M Orme
Journal:  Tuberculosis (Edinb)       Date:  2010-07-24       Impact factor: 3.131

3.  Enhanced priming of adaptive immunity by a proapoptotic mutant of Mycobacterium tuberculosis.

Authors:  Joseph Hinchey; Sunhee Lee; Bo Y Jeon; Randall J Basaraba; Manjunatha M Venkataswamy; Bing Chen; John Chan; Miriam Braunstein; Ian M Orme; Steven C Derrick; Sheldon L Morris; William R Jacobs; Steven A Porcelli
Journal:  J Clin Invest       Date:  2007-08       Impact factor: 14.808

4.  Long-term protection against tuberculosis following vaccination with a severely attenuated double lysine and pantothenate auxotroph of Mycobacterium tuberculosis.

Authors:  Vasan K Sambandamurthy; Steven C Derrick; Kripa V Jalapathy; Bing Chen; Robert G Russell; Sheldon L Morris; William R Jacobs
Journal:  Infect Immun       Date:  2005-02       Impact factor: 3.441

5.  Mycobacterium bovis BCG-mediated protection against W-Beijing strains of Mycobacterium tuberculosis is diminished concomitant with the emergence of regulatory T cells.

Authors:  Diane J Ordway; Shaobin Shang; Marcela Henao-Tamayo; Andres Obregon-Henao; Laura Nold; Megan Caraway; Crystal A Shanley; Randall J Basaraba; Colleen G Duncan; Ian M Orme
Journal:  Clin Vaccine Immunol       Date:  2011-07-27

Review 6.  Understanding latent tuberculosis: a moving target.

Authors:  Philana Ling Lin; Joanne L Flynn
Journal:  J Immunol       Date:  2010-07-01       Impact factor: 5.422

7.  Human T cell epitopes of Mycobacterium tuberculosis are evolutionarily hyperconserved.

Authors:  Iñaki Comas; Jaidip Chakravartti; Peter M Small; James Galagan; Stefan Niemann; Kristin Kremer; Joel D Ernst; Sebastien Gagneux
Journal:  Nat Genet       Date:  2010-05-23       Impact factor: 38.330

8.  Immunization with a mycobacterial lipid vaccine improves pulmonary pathology in the guinea pig model of tuberculosis.

Authors:  Christopher C Dascher; Kenji Hiromatsu; Xiaowei Xiong; Caroline Morehouse; Gerald Watts; Gui Liu; David N McMurray; Kenneth P LeClair; Steven A Porcelli; Michael B Brenner
Journal:  Int Immunol       Date:  2003-08       Impact factor: 4.823

9.  Lymphadenitis as a major element of disease in the guinea pig model of tuberculosis.

Authors:  Randall J Basaraba; Deanna D Dailey; Christine T McFarland; Crystal A Shanley; Erin E Smith; David N McMurray; Ian M Orme
Journal:  Tuberculosis (Edinb)       Date:  2006-02-10       Impact factor: 3.131

Review 10.  The immunological life cycle of tuberculosis.

Authors:  Joel D Ernst
Journal:  Nat Rev Immunol       Date:  2012-07-13       Impact factor: 53.106

View more
  22 in total

Review 1.  Current trends in tuberculosis vaccine.

Authors:  J S V Soundarya; Uma Devi Ranganathan; Srikanth P Tripathy
Journal:  Med J Armed Forces India       Date:  2019-01-18

2.  Mycobacterial Hsp65 antigen upregulates the cellular immune response of healthy individuals compared with tuberculosis patients.

Authors:  Pryscilla Fanini Wowk; Luís Henrique Franco; Denise Morais da Fonseca; Marina Oliveira Paula; Élcio Dos Santos Oliveira Vianna; Ana Paula Wendling; Valéria Maria Augusto; Silvana Maria Elói-Santos; Andréa Teixeira-Carvalho; Flávia Dias Coelho Silva; Solange Alves Vinhas; Olindo Assis Martins-Filho; Moisés Palaci; Célio Lopes Silva; Vânia Luiza Deperon Bonato
Journal:  Hum Vaccin Immunother       Date:  2017-01-06       Impact factor: 3.452

3.  Principles in Immunology for the Design and Development of Vaccines.

Authors:  Claudius U Meyer; Fred Zepp
Journal:  Methods Mol Biol       Date:  2022

4.  Cyclic-di-AMP Phosphodiesterase Elicits Protective Immune Responses Against Mycobacterium tuberculosis H37Ra Infection in Mice.

Authors:  Yanzhi Lu; Huanhuan Ning; Jian Kang; Guangchun Bai; Lei Zhou; Yali Kang; Zhengfeng Wu; Maolin Tian; Junhao Zhao; Yueyun Ma; Yinlan Bai
Journal:  Front Cell Infect Microbiol       Date:  2022-06-22       Impact factor: 6.073

5.  Protection and Long-Lived Immunity Induced by the ID93/GLA-SE Vaccine Candidate against a Clinical Mycobacterium tuberculosis Isolate.

Authors:  Susan L Baldwin; Valerie A Reese; Po-Wei D Huang; Elyse A Beebe; Brendan K Podell; Steven G Reed; Rhea N Coler
Journal:  Clin Vaccine Immunol       Date:  2015-12-09

6.  Vaccine-mediated immunity to experimental Mycobacterium tuberculosis is not impaired in the absence of Toll-like receptor 9.

Authors:  Archana Gopalakrishnan; Jillian Dietzold; Padmini Salgame
Journal:  Cell Immunol       Date:  2015-12-30       Impact factor: 4.868

7.  Induction of Unconventional T Cells by a Mutant Mycobacterium bovis BCG Strain Formulated in Cationic Liposomes Correlates with Protection against Mycobacterium tuberculosis Infections of Immunocompromised Mice.

Authors:  Steven C Derrick; Idalia Yabe; Sheldon Morris; Siobhan Cowley
Journal:  Clin Vaccine Immunol       Date:  2016-07-05

8.  Eukaryotic-Type Ser/Thr Protein Kinase Mediated Phosphorylation of Mycobacterial Phosphodiesterase Affects its Localization to the Cell Wall.

Authors:  Neha Malhotra; Pradip K Chakraborti
Journal:  Front Microbiol       Date:  2016-02-09       Impact factor: 5.640

9.  New Genome-Wide Algorithm Identifies Novel In-Vivo Expressed Mycobacterium Tuberculosis Antigens Inducing Human T-Cell Responses with Classical and Unconventional Cytokine Profiles.

Authors:  Mariateresa Coppola; Krista E van Meijgaarden; Kees L M C Franken; Susanna Commandeur; Gregory Dolganov; Igor Kramnik; Gary K Schoolnik; Inaki Comas; Ole Lund; Corine Prins; Susan J F van den Eeden; Gro E Korsvold; Fredrik Oftung; Annemieke Geluk; Tom H M Ottenhoff
Journal:  Sci Rep       Date:  2016-11-28       Impact factor: 4.379

Review 10.  A review of clinical models for the evaluation of human TB vaccines.

Authors:  Matthew K O'Shea; Helen McShane
Journal:  Hum Vaccin Immunother       Date:  2016-01-25       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.